HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- VTE risk in patients with cancer often overlooked understudied
-
- Personalized T-cell therapy yields promising outcomes in relapsed, refractory CLL
- Hematology Drugs in the Pipeline
- Peto's paradox: Elephants, whales, Chihuahuas and cancer Derek Raghavan, MD, PhD, FACP, FRACP, FASCO
- FDA approves Coagadex for hereditary Factor X deficiency
- FDA approves Onivyde as part of combination regimen for treatment of metastatic pancreatic cancer
- FDA approves Praxbind for Pradaxa reversal
- FDA approves ultrasound system for targeted prostate treatment
- FDA approves Yondelis for treatment of specific unresectable or metastatic soft tissue sarcomas
-
- FDA grants avelumab fast track designation for metastatic Merkel cell carcinoma
- FDA grants breakthrough therapy designation to inotuzumab ozogamicin for ALL
- FDA grants orphan drug designation to STM 434 for ovarian cancer
- ACS updates breast cancer screening guideline for average-risk women
- Allogeneic HSCT recipients face increased risk for skin cancer
- Anticoagulation appears safe, effective in patients with splanchnic vein thrombosis
- Azacitidine improves survival for older patients with AML
- Bevacizumab improves pathological complete response in HER-2–negative early breast cancer
-
- Cancer remains the leading cause of death among US Hispanics
- Chemotherapy plus bevacizumab extends survival in epithelial ovarian cancer
- Chemotherapy plus ponatinib may improve Ph+ALL outcomes
- Circulating tumor cells predict decreased survival in cholangiocarcinoma
- Colorectal cancer in adolescents, young adults more likely to have had heredity predisposition
- Financial penalties for hospital-acquired VTE do not account for unpreventable incidents
- Gastrointestinal stromal tumors increase risk for additional malignancies
- Health insurance coverage varies by patient demographics, cancer type
-
- HIV-associated Hodgkin’s lymphoma patients benefit from cART, ABVD
- Hospital protocol improves care for children with sickle cell disease
- HSCT improves survival for older patients with multiple myeloma
- Idarucizumab rapidly reverses anticoagulant effect of dabigatran, restores hemostasis
- Including arsenic trioxide in induction, consolidation therapy shows promise for APL
- IVC filter retrieval rate high with minimal complications
- Kallikrein markers improve high-grade prostate cancer detection, reduce unnecessary biopsies
- Long-term survival for patients with ovarian cancer higher than expected
-
- Many women with early-stage breast cancer receive imaging, despite practice guidelines
- Mohs micrographic surgery delays not tied to nonmelanoma skin cancer tumor growth
- Molecular prognostic index may predict survival in early-stage NSCLC
- Morbidity increases among childhood cancer survivors
- One alcoholic drink daily may increase risk for cancer in women
- Past breast-feeding may decrease risk for breast cancer recurrence, death
- Persistent mutations may predict EFS, OS outcomes in AML
- Positive post-radiation biopsy may predict worse outcomes for early-stage prostate cancer
-
- Racial, insurance disparities influence chemotherapy receipt for colon cancer
- Review examines presentation, course of major bleeding events during anticoagulation therapy
- T-cell therapy leads to complete response in patient with refractory multiple myeloma
- Triplet combination increases MRD negativity in multiple myeloma
- Tumor mutations, survival in stage 3 colon cancer differ by race
- Vertebral fractures common among children with ALL
- Vismodegib appears effective in medulloblastoma subtype
- Vitamin K antagonists do not affect bone mineral density, fracture risk
-
- American College of Gastroenterology elects new president
- American Society of Preventive Oncology names next president
- ASH presents honors awards to 28 medical students, residents
- Association of American Cancer Institutes presents award
- Association of Pediatric Hematology/Oncology Nurses presents awards
- ASTRO presents Annual Meeting Nurses Abstract Award
- Beth Israel Deaconess Medical Center names cancer center director
- Fox Chase researcher earns American Cancer Society honor
-
- Medical College of Wisconsin appoints senior associate dean
- NYU Langone appoints chair of radiation oncology
- Adjuvant APBI with multicatheter brachytherapy effective for early-stage breast cancer
- Aggressive multimodal therapy may improve outcomes for anaplastic thyroid cancer
- Answer to common clinical question may predict risk for death
- Cabozantinib safe, effective in advanced, refractory differentiated thyroid cancer
- Cabozantinib significantly prolongs OS in patients with RET-mutated medullary thyroid cancer
- Children with ependymoma experience favorable outcomes with immediate postoperative radiation
-
- Daily aspirin increases chance of gastrointestinal cancer survival
- Despite guideline revisions, total thyroidectomy often still needed in well-differentiated thyroid cancer
- Follow-up by advance practice nurses improves care for patients with head, neck cancer
- IMRT for locally advanced NSCLC reduces risk for severe pneumonitis
- Metastatic lymph node size, extension predict PTC recurrence risk
- Molecular differences found between tumors of younger, older CRC patients
- Molecular markers predict metastases, therapy response in medullary thyroid cancer
- Nivolumab, ipilimumab combination improves PFS in advanced melanoma regardless of prognostic factors
-
- Nivolumab ‘likely to change the treatment’ of advanced renal cell carcinoma
- Papillary thyroid cancer outcomes have significantly improved over time
- PD-L1 expression influences DFS, therapy response in papillary thyroid cancer
- Surgical treatment improves OS in advanced throat cancers
- Thyroglobulin level, prior therapy do not predict pazopanib response in differentiated thyroid cancer